Cargando…

A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia

BACKGROUND: Polypharmacy is common in people with dementia. The use of psychotropic drugs (PDs) and other, potentially inappropriate medications is high. The aims of this cross-sectional study were 1) to investigate the use of drugs in people with advanced dementia (PWAD), living at home or in long...

Descripción completa

Detalles Bibliográficos
Autores principales: Riedl, Lina, Kiesel, Esther, Hartmann, Julia, Fischer, Julia, Roßmeier, Carola, Haller, Bernhard, Kehl, Victoria, Priller, Josef, Trojan, Monika, Diehl-Schmid, Janine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925050/
https://www.ncbi.nlm.nih.gov/pubmed/35296254
http://dx.doi.org/10.1186/s12877-022-02914-x
_version_ 1784669985637924864
author Riedl, Lina
Kiesel, Esther
Hartmann, Julia
Fischer, Julia
Roßmeier, Carola
Haller, Bernhard
Kehl, Victoria
Priller, Josef
Trojan, Monika
Diehl-Schmid, Janine
author_facet Riedl, Lina
Kiesel, Esther
Hartmann, Julia
Fischer, Julia
Roßmeier, Carola
Haller, Bernhard
Kehl, Victoria
Priller, Josef
Trojan, Monika
Diehl-Schmid, Janine
author_sort Riedl, Lina
collection PubMed
description BACKGROUND: Polypharmacy is common in people with dementia. The use of psychotropic drugs (PDs) and other, potentially inappropriate medications is high. The aims of this cross-sectional study were 1) to investigate the use of drugs in people with advanced dementia (PWAD), living at home or in long term care (LTC); 2) to focus on PD use; and 3) to identify determinants of PD use. METHODS: The study was performed in the context of EPYLOGE (IssuEs in Palliative care for people in advanced and terminal stages of YOD and LOD in Germany). 191 PWAD were included. All drugs that were administered at the date of the examination were recorded. Multiple logistic regression analysis identified determinants of PD use. RESULTS: 96% of PWAD received medication with a median number of four drugs. 49.7% received five or more drugs. According to the Beers Criteria 39% of PWAD ≥ 65 years received at least one potentially inappropriate medication. 79% of PWAD were treated with PDs. Older PWAD and PWAD living in LTC facilities received significantly more drugs than younger PWAD, and PWAD living at home, respectively. Dementia etiology was significantly associated with the use of antipsychotics, antidepressants and sedative substances. Place of living was associated with the use of pain medication. Behavioral disturbances were associated with the use of antipsychotics and sedative substances. CONCLUSIONS: To mitigate the dangers of polypharmacy and medication related harm, critical examination is required, whether a drug is indicated or not. Also, the deprescribing of drugs should be considered on a regular basis. TRIAL REGISTRATION: Clinicaltrial.gov, NCT03364179. Registered 6 December 2017.
format Online
Article
Text
id pubmed-8925050
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89250502022-03-23 A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia Riedl, Lina Kiesel, Esther Hartmann, Julia Fischer, Julia Roßmeier, Carola Haller, Bernhard Kehl, Victoria Priller, Josef Trojan, Monika Diehl-Schmid, Janine BMC Geriatr Research BACKGROUND: Polypharmacy is common in people with dementia. The use of psychotropic drugs (PDs) and other, potentially inappropriate medications is high. The aims of this cross-sectional study were 1) to investigate the use of drugs in people with advanced dementia (PWAD), living at home or in long term care (LTC); 2) to focus on PD use; and 3) to identify determinants of PD use. METHODS: The study was performed in the context of EPYLOGE (IssuEs in Palliative care for people in advanced and terminal stages of YOD and LOD in Germany). 191 PWAD were included. All drugs that were administered at the date of the examination were recorded. Multiple logistic regression analysis identified determinants of PD use. RESULTS: 96% of PWAD received medication with a median number of four drugs. 49.7% received five or more drugs. According to the Beers Criteria 39% of PWAD ≥ 65 years received at least one potentially inappropriate medication. 79% of PWAD were treated with PDs. Older PWAD and PWAD living in LTC facilities received significantly more drugs than younger PWAD, and PWAD living at home, respectively. Dementia etiology was significantly associated with the use of antipsychotics, antidepressants and sedative substances. Place of living was associated with the use of pain medication. Behavioral disturbances were associated with the use of antipsychotics and sedative substances. CONCLUSIONS: To mitigate the dangers of polypharmacy and medication related harm, critical examination is required, whether a drug is indicated or not. Also, the deprescribing of drugs should be considered on a regular basis. TRIAL REGISTRATION: Clinicaltrial.gov, NCT03364179. Registered 6 December 2017. BioMed Central 2022-03-16 /pmc/articles/PMC8925050/ /pubmed/35296254 http://dx.doi.org/10.1186/s12877-022-02914-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Riedl, Lina
Kiesel, Esther
Hartmann, Julia
Fischer, Julia
Roßmeier, Carola
Haller, Bernhard
Kehl, Victoria
Priller, Josef
Trojan, Monika
Diehl-Schmid, Janine
A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia
title A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia
title_full A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia
title_fullStr A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia
title_full_unstemmed A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia
title_short A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia
title_sort bitter pill to swallow - polypharmacy and psychotropic treatment in people with advanced dementia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925050/
https://www.ncbi.nlm.nih.gov/pubmed/35296254
http://dx.doi.org/10.1186/s12877-022-02914-x
work_keys_str_mv AT riedllina abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT kieselesther abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT hartmannjulia abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT fischerjulia abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT roßmeiercarola abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT hallerbernhard abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT kehlvictoria abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT prillerjosef abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT trojanmonika abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT diehlschmidjanine abitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT riedllina bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT kieselesther bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT hartmannjulia bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT fischerjulia bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT roßmeiercarola bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT hallerbernhard bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT kehlvictoria bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT prillerjosef bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT trojanmonika bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia
AT diehlschmidjanine bitterpilltoswallowpolypharmacyandpsychotropictreatmentinpeoplewithadvanceddementia